1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Rivaroxaban API Manufacturers | Patent

Rivaroxaban US-Exclusivity -API-Small Molecules

Back

All Download Excel File

Show entries

Search:

Application Type	Application No	Trade Name	Active Ingredient	Exclusivity Type	Exclusivity Explanation	Exclusivity Expiry Date

Application Type	Application No	Trade Name	Active Ingredient	Exclusivity Type	Exclusivity Explanation	Exclusivity Expiry Date
N	22406	Xarelto	Rivaroxaban	D-168	New Dosing Regimen Of 10 Mg Once Daily For The Reduction In The Risk Of Recurrence Of Deep Vein Thrombosis (Dvt) And/Or Pulmonary Embolism (Pe) In Patients At Continued Risk For Dvt And/Or Pe After Completion Of Initial Treatment Lasting At Least 6 Months	2020-10-27

Showing 1 to 3 of 3 entries

Previous1Next

Cookies & Privacy

This website uses ‘cookies’ to operate our site and personalize your digital experience. By continuing to browse this website, you agree to the terms outlined in our Privacy Policy, Cookies Policy

Rivaroxaban US-Exclusivity -API-Small Molecules

Advance Filter

Supplier

Cookies & Privacy

Select cookies to accept